Originally published as JCO Early Release 10.1200/JCO.2004.01.153 on August 23 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hotta, K. Articles by Tanimoto, M. Search for Related Content PubMed PubMed Citation Articles by Hotta, K. Articles by Tanimoto, M. Related Articles Related Article Related Editorial Related Correspondence Social Bookmarking                            What's this?

Role of Adjuvant Chemotherapy in Patients With Resected Non–Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials

From the Department of Medicine II, Okayama University Medical School, Okayama; Department of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.

Address reprint requests to Katsuyuki Hotta, MD, Department of Medicine II, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama, 700-8558, Japan; e-mail: khotta{at}md.okayama-u.ac.jp

PURPOSE: The role of adjuvant chemotherapy in patients with resected non–small-cell lung cancer (NSCLC) remains to be defined. This study was aimed at re-evaluating the effectiveness of adjuvant chemotherapy in patients with resected NSCLC, by performing a meta-analysis of relevant trials.

METHODS: We performed a literature search to identify trials reported after the publication of a meta-analysis in 1995, comparing patients with NSCLC receiving chemotherapy after surgery with those undergoing surgery alone. The hazard ratio (HR) was estimated to assess the survival advantage of adjuvant chemotherapy.

RESULTS: Eleven trials conducted on a total of 5,716 patients were identified by the literature search. In these trials, hazard ratio estimates suggested that adjuvant chemotherapy yielded a survival advantage over surgery alone (HR, 0.872; 95% CI, 0.805 to 0.944; P = .001). In a subset analysis, both cisplatin-based chemotherapy (HR, 0.891; 95% CI, 0.815 to 0.975; P = .012) and single-agent therapy with tegafur and uracil (UFT; HR, 0.799; 95% CI, 0.668 to 0.957; P = .015) were found to yield a significant survival benefit. The toxicities of adjuvant chemotherapy were found to be generally mild.

CONCLUSION: This is the first updated meta-analysis demonstrating the importance of cisplatin-based chemotherapy and single-agent UFT therapy as adjuvant chemotherapy in the treatment of resected NSCLC. Although the results must be carefully interpreted because of one limitation (the meta-analysis was performed with abstracted data), they raise critical issues that must be resolved in future studies.

Katsuyuki Hotta and Keitaro Matsuo contributed equally to this work.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

• Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
  Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, and Mitsune Tanimoto
  JCO 2004 22: 3852-3859 [Abstract] [Full Text]

Related Editorial

• Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step
  Pascal Piedbois and Marc Buyse
  JCO 2004 22: 3839-3841 [Full Text]

Related Correspondence

• Chemotherapy in Non-Small-Cell Lung Cancer: An Update of an Individual Patient Data Meta-Analysis
  Sarah Burdett, Lesley Stewart, Anne Auperin, and Jean-Pierre Pignon
  JCO 2005 23: 924-925 [Full Text]
• They Also Serve Who Only Stand and Wait: Do Individual Clinical Researchers, Too? Hoping for Individual Patient Data As Public Domain
  Keitaro Matsuo, Katsuyuki Hotta, and Hiroshi Ueoka
  JCO 2005 23: 1334-1335 [Full Text]

This article has been cited by other articles:

				V. K. Anagnostou, K. N. Syrigos, G. Bepler, R. J. Homer, and D. L. Rimm Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma J. Clin. Oncol., January 10, 2009; 27(2): 271 - 278. [Abstract] [Full Text] [PDF]

				J.-P. Pignon, H. Tribodet, G. V. Scagliotti, J.-Y. Douillard, F. A. Shepherd, R. J. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group J. Clin. Oncol., July 20, 2008; 26(21): 3552 - 3559. [Abstract] [Full Text] [PDF]

				K. M.W. Pisters, W. K. Evans, C. G. Azzoli, M. G. Kris, C. A. Smith, C. E. Desch, M. R. Somerfield, M. C. Brouwers, G. Darling, P. M. Ellis, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline J. Clin. Oncol., December 1, 2007; 25(34): 5506 - 5518. [Abstract] [Full Text] [PDF]

				H. Suehisa, S. Toyooka, K. Hotta, A. Uchida, J. Soh, Y. Fujiwara, K. Matsuo, M. Ouchida, M. Takata, K. Kiura, et al. Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung J. Clin. Oncol., September 1, 2007; 25(25): 3952 - 3957. [Abstract] [Full Text] [PDF]

				K. Aokage, G. Ishii, K. Nagai, O. Kawai, Y. Naito, T. Hasebe, M. Nishimura, J. Yoshida, and A. Ochiai Intrapulmonary metastasis in resected pathologic stage IIIB non small cell lung cancer: Possible contribution of aerogenous metastasis to the favorable outcome J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 386 - 391. [Abstract] [Full Text] [PDF]

				P. Seve, R. Lai, K. Ding, T. Winton, C. Butts, J. Mackey, C. Dumontet, L. Dabbagh, S. Aviel-Ronen, L. Seymour, et al. Class III {beta}-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10 Clin. Cancer Res., February 1, 2007; 13(3): 994 - 999. [Abstract] [Full Text] [PDF]

				C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer Oncologist, February 1, 2007; 12(2): 191 - 200. [Abstract] [Full Text] [PDF]

				R. A. Juergens and J. R. Brahmer Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now? J Natl Compr Canc Netw, July 1, 2006; 4(6): 595 - 600. [Abstract] [PDF]

				N. Alam, G. Darling, F. A. Shepherd, J. A. Mackay, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. Ann. Thorac. Surg., May 1, 2006; 81(5): 1926 - 1936. [Abstract] [Full Text] [PDF]

				I. Park, K. Y. Chung, K. D. Kim, and D. J. Kim Prognostic Factors for Disease-Free Survival in pT2N0 Non-Small Cell Lung Cancer Asian Cardiovasc Thorac Ann, April 1, 2006; 14(2): 139 - 144. [Abstract] [Full Text] [PDF]

				A. Auperin, C. Le Pechoux, J. P. Pignon, C. Koning, B. Jeremic, G. Clamon, L. Einhorn, D. Ball, M. G. Trovo, H. J. M. Groen, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients Ann. Onc., March 1, 2006; 17(3): 473 - 483. [Abstract] [Full Text] [PDF]

				P. Maione, C. Gridelli, T. Troiani, and F. Ciardiello Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC. Oncologist, March 1, 2006; 11(3): 274 - 284. [Abstract] [Full Text] [PDF]

				O. Belvedere and F. Grossi Lung Cancer Highlights from ASCO 2005 Oncologist, January 1, 2006; 11(1): 39 - 50. [Abstract] [Full Text] [PDF]

				A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2933 - 2943. [Abstract] [Full Text] [PDF]

				C. Hamada, F. Tanaka, M. Ohta, S. Fujimura, K. Kodama, M. Imaizumi, and H. Wada Meta-Analysis of Postoperative Adjuvant Chemotherapy With Tegafur-Uracil in Non-Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4999 - 5006. [Abstract] [Full Text] [PDF]

				L. Wilhelm and J. M. Kolesar Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1365 - 1369. [Abstract] [Full Text] [PDF]

				K. M.W. Pisters and T. Le Chevalier Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3270 - 3278. [Abstract] [Full Text] [PDF]

				S. Burdett, L. Stewart, and J.-P. Pignon Chemotherapy in non-small cell lung cancer: An update of an individual patient data-based meta-analysis J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1205 - 1205. [Full Text] [PDF]

				K. Matsuo, K. Hotta, and H. Ueoka They Also Serve Who Only Stand and Wait: Do Individual Clinical Researchers, Too? Hoping for Individual Patient Data As Public Domain J. Clin. Oncol., February 20, 2005; 23(6): 1334 - 1335. [Full Text] [PDF]

				S. Burdett, L. Stewart, A. Auperin, and J.-P. Pignon Chemotherapy in Non-Small-Cell Lung Cancer: An Update of an Individual Patient Data Meta-Analysis J. Clin. Oncol., February 1, 2005; 23(4): 924 - 925. [Full Text] [PDF]

				K. Hotta, K. Matsuo, and H. Ueoka In Reply: J. Clin. Oncol., February 1, 2005; 23(4): 925 - 926. [Full Text] [PDF]

				P. Piedbois and M. Buyse Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step J. Clin. Oncol., October 1, 2004; 22(19): 3839 - 3841. [Full Text] [PDF]